Mike Pellini built and ran companies like Clarient and Foundation Medicine before becoming an investor, so he tends to judge deals on operating experience—things like changing physician workflow, sharing genomic data broadly, and proving out reimbursement early—rather than science alone. He also focuses on getting precision medicine and cancer screening to more everyday hospitals and patients, not just top academic centers, and prefers to stay behind the scenes rather than put himself at the center of attention.